Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas

Authors
Kwak, H-JKim, Y-JChun, K-RWoo, Y. M.Park, S-JJeong, J-AJo, S. H.Kim, T. H.Min, H. S.Chae, J. S.Choi, E-JKim, G.Shin, S-HGwak, H-SKim, S-KHong, E-KLee, G-KChoi, K-HKim, J. H.Yoo, H.Park, J. B.Lee, S-H
Issue Date
May-2011
Publisher
NATURE PUBLISHING GROUP
Keywords
glioma; invasion; hyaluronan; miR-21; spry2; PTEN
Citation
ONCOGENE, v.30, no.21, pp.2433 - 2442
Indexed
SCIE
SCOPUS
Journal Title
ONCOGENE
Volume
30
Number
21
Start Page
2433
End Page
2442
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/112509
DOI
10.1038/onc.2010.620
ISSN
0950-9232
Abstract
Gliomas are associated with high mortality because of their exceedingly invasive character. As these tumors acquire their invasiveness from low-grade tumors, it is very important to understand the detailed molecular mechanisms of invasion onset. Recent evidences suggest the significant role of microRNAs in tumor invasion. Thus, we hypothesized that deregulation of microRNAs may be important for the malignant progression of gliomas. We found that the aberrant expression of miR-21 is responsible for glioma invasion by disrupting the negative feedback circuit of Ras/MAPK signaling, which is mediated by Spry2. Upregulation of miR-21 was triggered by tumor microenvironmental factors such as hyaluronan and growth factors in glioma cells lacking functional phosphatase and tensin homolog (PTEN), but not harboring wild-type PTEN. Consistently with these in vitro results, Spry2 protein levels were significantly decreased in 79.7% of invasive WHO grade II-IV human glioma tissues, but not in non-invasive grade I and normal tissues. The Spry2 protein levels were not correlated with their mRNA levels, but inversely correlated with miR-21 levels. Taken together, these results suggest that the post-transcriptional regulation of Spry2 by miR-21 has an essential role on the malignant progression of human gliomas. Thus, Spry2 may be a novel therapeutic target for treating gliomas. Oncogene (2011) 30, 2433-2442; doi:10.1038/onc.2010.620; published online 31 January 2011
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Life Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE